AM-Pharma announces the appointment of Bart Wuurman as CEO

February 7 2007 | Category: Appointment

Bart Wuurman, M. Sc. replaces Bruno Giannetti, MD., Ph.D., who left AM-Pharma in December 2006. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry experience with Organon, Medeva and Antisoma, where he was responsible for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of De Novo Pharmaceuticals in Cambridge, UK, where he successfully implemented a restructuring and refinancing strategy.

Bart Wuurman, M. Sc., CEO of AM-Pharma comments: “With its two innovative products in Phase II, promising clinical data and a healthy financial position, AM-Pharma stands out in the EU biotech arena. I am very happy with my appointment because AM-Pharma presents a great opportunity for strong short term value growth.”

Prof. Eric Claassen, Chairman of AM-Pharma comments: “We are very excited about the appointment of Bart Wuurman. He brings a wealth of biotechnology experience, a commercial focus and a relevant international network, which is exactly what AM-Pharma needs now that its products are generating such exciting clinical results.”

Latest News

October 24 2018
JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury
Read more.

March 9 2018
AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury
Read more.

News Categories


Upcoming Events

For a full list of the events we will be attending this year
Click here.